Description: INmune Bio, Inc. is a clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors.
Home Page: www.inmunebio.com
INMB Technical Analysis
980 North Federal Highway
Boca Raton,
FL
33432
United States
Phone:
858 964 3720
Officers
| Name | Title |
|---|---|
| Dr. Raymond Joseph Tesi M.D. | Co-Founder, Pres, CEO, Chief Medical Officer & Chairman |
| Mr. David J. Moss M.B.A. | CFO, Treasurer & Sec. |
| Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. | Chief Scientific Officer & Chief Manufacturing Officer |
| Mr. Joshua S. Schoonover Esq. | Assoc. Gen. Counsel |
| Dr. Christopher J. Barnum | Head of Neuroscience |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.155 |
| Price-to-Sales TTM: | 306.3056 |
| IPO Date: | 2019-02-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |